Received 2 April 2010
The title compound, C16H20F3N3O4, was prepared by reaction of 4-(dimethylamino)benzaldehyde, ethyl 4,4,4-trifluoro-3-oxobutanoate and urea. In the title molecule, the pyrimidine ring adopts a half-chair conformation and there is an intramolecular hydrogen bond (O-HO). The crystal structure is stabilized by two types intermolecular hydrogen bonds (N-HO and N-HN).
For the bioactivity of dihydropyrimidines, see: Brier et al. (2004); Cochran et al. (2005); Moran et al. (2007); Zorkun et al. (2006). For the bioactivity of organofluorine compounds, see: Hermann et al. (2003); Ulrich (2004).
Data collection: CrystalClear (Rigaku/MSC, 2005); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication: CrystalStructure (Rigaku/MSC, 2005).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: OM2331 ).
This work was supported by the Natural Science Foundation of Henan Province, China (grant No. 082300420110), and the Natural Science Foundation of Henan Province Education Department, China (grant No. 2007150036).
Brier, S., Lemaire, D., DeBonis, S., Forest, E. & Kozielski, F. (2004). Biochemistry, 43, 13072-13082.
Cochran, J. C., Gatial, J. E., Kapoor, T. M. & Gilbert, S. P. (2005). J. Biol. Chem. 280, 12658-12667.
Hermann, B., Erwin, H. & Hansjorg, K. (2003). US Patent No. 2003176284.
Moran, M. M., Fanger, C., Chong, J. A., McNamara, C., Zhen, X. G. & &Mandel-Brehm, J. (2007). WO Patent No. 2007073505.
Rigaku/MSC (2005). CrystalClear and CrystalStructure. Rigaku/MSC, The Woodlands, Texas, USA.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
Ulrich, H. (2004). US Patent No. 2004033897.
Zorkun, I. S., Sarac, S., Celebi, S. & Erol, K. (2006). Bioorg. Med. Chem. 14, 8582-8589.